RxDoctor Payments Data

Glenn Esses, MD

Vascular Surgery · Mobile, ALNPI 1912900283

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations.

$6,760in general payments, 2019–2025

Across 180 payments — averaging $37.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Endologix LLC$571
  • Cook Medical LLC$353
  • Baxter Healthcare$319
  • Silk Road Medical, Inc.$254
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$6,45495%
  • Education$2934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,760 in reported general payments places this provider in the 55th percentile of 61 vascular surgery providers in Alabama.

See all vascular surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$360,349
Medicare patients
495
Services billed
1,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban71$47,497
EliquisApixaban49$32,018
Prasugrel Hcl26$1,176
ClopidogrelClopidogrel Bisulfate104$917
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen98$630
Rosuvastatin Calcium22$190
Methylprednisolone11$71
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$57
Levofloxacin12$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$193$47,49771 claims
PfizerEliquis$79$32,01849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 61 vascular surgery providers in Alabama.

Other vascular surgery in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →